4XB.F · XBiotech Inc

-

Please sign in to comment on 4XB.F

1 Comment

Admin

4 years, 1 month ago

XBiotech Inc is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.

From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.8.

XBiotech Inc's total revenue rose by inf% to $5M since the same quarter in the previous year.

Its net income has dropped by 100.3% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 30.5% to $-3M since the same quarter in the previous year.

Based on the above factors, XBiotech Inc gets an overall score of 3/5.

Exchange	F
CurrencyCode	EUR
ISIN	CA98400H1029
Sector	Healthcare
Industry	Biotechnology

Beta	1.28
Market Cap	80M
PE Ratio	None
Target Price	None
Dividend Yield	None

ABOUT

XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

4XB.F · XBiotech Inc

-

XBiotech Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest XBiotech Inc using a moving average strategy